179 related articles for article (PubMed ID: 36684904)
41. Incidence of human papillomavirus-related cancers among males and females aged 15-34 years in the United States.
Guo F; Adekanmbi V; Hsu CD; Berenson AB
JNCI Cancer Spectr; 2023 Mar; 7(2):. PubMed ID: 36821427
[TBL] [Abstract][Full Text] [Related]
42. Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008-2015.
Cleveland AA; Gargano JW; Park IU; Griffin MR; Niccolai LM; Powell M; Bennett NM; Saadeh K; Pemmaraju M; Higgins K; Ehlers S; Scahill M; Johnson Jones ML; Querec T; Markowitz LE; Unger ER;
Int J Cancer; 2020 Feb; 146(3):810-818. PubMed ID: 30980692
[TBL] [Abstract][Full Text] [Related]
43. Trends in incidence and mortality rates of squamous cell carcinoma and adenocarcinoma of cervix--worldwide.
Mathew A; George PS
Asian Pac J Cancer Prev; 2009; 10(4):645-50. PubMed ID: 19827887
[TBL] [Abstract][Full Text] [Related]
44. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
Gomez JA; Lepetic A; Demarteau N
BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
[TBL] [Abstract][Full Text] [Related]
45. Cytology and cervical cancer surveillance in an era of human papillomavirus vaccination.
Budd AC; Sturrock CJ
Sex Health; 2010 Sep; 7(3):328-34. PubMed ID: 20719223
[TBL] [Abstract][Full Text] [Related]
46. The impact of over ten years of HPV vaccination in England: Surveillance of type-specific HPV in young sexually active females.
Checchi M; Mesher D; Panwar K; Anderson A; Beddows S; Soldan K
Vaccine; 2023 Oct; 41(45):6734-6744. PubMed ID: 37821315
[TBL] [Abstract][Full Text] [Related]
47. Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria.
Boiron L; Joura E; Largeron N; Prager B; Uhart M
BMC Infect Dis; 2016 Apr; 16():153. PubMed ID: 27084683
[TBL] [Abstract][Full Text] [Related]
48. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine.
Goldie SJ; Grima D; Kohli M; Wright TC; Weinstein M; Franco E
Int J Cancer; 2003 Oct; 106(6):896-904. PubMed ID: 12918067
[TBL] [Abstract][Full Text] [Related]
49. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment.
Hildesheim A; Gonzalez P; Kreimer AR; Wacholder S; Schussler J; Rodriguez AC; Porras C; Schiffman M; Sidawy M; Schiller JT; Lowy DR; Herrero R;
Am J Obstet Gynecol; 2016 Aug; 215(2):212.e1-212.e15. PubMed ID: 26892991
[TBL] [Abstract][Full Text] [Related]
50. Missed Opportunities for HPV Vaccination Among Vaccine-Eligible Women with High Grade Cervical Lesions.
Russ SM; Brackney M; Meek J; Niccolai LM
Vaccine; 2019 Jul; 37(31):4262-4267. PubMed ID: 31248688
[TBL] [Abstract][Full Text] [Related]
51. Comparison of the long-term impact and clinical outcomes of fewer doses and standard doses of human papillomavirus vaccine in the United States: A database study.
Rodriguez AM; Zeybek B; Vaughn M; Westra J; Kaul S; Montealegre JR; Lin YL; Kuo YF
Cancer; 2020 Apr; 126(8):1656-1667. PubMed ID: 32037524
[TBL] [Abstract][Full Text] [Related]
52. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
Armstrong EP
J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
[TBL] [Abstract][Full Text] [Related]
53. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
[TBL] [Abstract][Full Text] [Related]
54. Trends in cervical cancer incidence rates by age, race/ethnicity, histological subtype, and stage at diagnosis in the United States.
Islami F; Fedewa SA; Jemal A
Prev Med; 2019 Jun; 123():316-323. PubMed ID: 31002830
[TBL] [Abstract][Full Text] [Related]
55. Assessing the epidemiological impact on cervical cancer of switching from 4-valent to 9-valent HPV vaccine within a gender-neutral vaccination programme in Switzerland.
Kind AB; Pavelyev A; Kothari S; El Mouaddin N; Schmidt A; Morais E; Guggisberg P; Lienert F
BMC Public Health; 2020 May; 20(1):671. PubMed ID: 32398057
[TBL] [Abstract][Full Text] [Related]
56. Efficacy of vaccination against HPV infections to prevent cervical cancer in France: present assessment and pathways to improve vaccination policies.
Ribassin-Majed L; Lounes R; Clémençon S
PLoS One; 2012; 7(3):e32251. PubMed ID: 22427828
[TBL] [Abstract][Full Text] [Related]
57. Potential benefit of extended dose schedules of human papillomavirus vaccination in the context of scarce resources and COVID-19 disruptions in low-income and middle-income countries: a mathematical modelling analysis.
Bénard É; Drolet M; Laprise JF; Jit M; Prem K; Boily MC; Brisson M
Lancet Glob Health; 2023 Jan; 11(1):e48-e58. PubMed ID: 36521952
[TBL] [Abstract][Full Text] [Related]
58. Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: establishing the baseline for surveillance.
Nygård M; Hansen BT; Dillner J; Munk C; Oddsson K; Tryggvadottir L; Hortlund M; Liaw KL; Dasbach EJ; Kjær SK
PLoS One; 2014; 9(2):e88323. PubMed ID: 24505474
[TBL] [Abstract][Full Text] [Related]
59. Human Papillomavirus Vaccination and Cervical Cytology Outcomes Among Urban Low-Income Minority Females.
Hofstetter AM; Ompad DC; Stockwell MS; Rosenthal SL; Soren K
JAMA Pediatr; 2016 May; 170(5):445-52. PubMed ID: 26974250
[TBL] [Abstract][Full Text] [Related]
60. The potential impact of prophylactic human papillomavirus vaccination on oropharyngeal cancer.
Guo T; Eisele DW; Fakhry C
Cancer; 2016 Aug; 122(15):2313-23. PubMed ID: 27152637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
